FDA recalls 90,000 bottles of children's ibuprofen over contamination fears

The U.S. Food and Drug Administration (FDA) has ordered a recall of nearly 90,000 bottles of Children's Ibuprofen Oral Suspension. The berry-flavoured medication, meant for children aged 2 to 11, was pulled from shelves after customers reported finding unusual contaminants inside.

The recall affects a liquid ibuprofen product manufactured by Strides Pharma Inc. in India for Taro Pharmaceuticals. Several customers noticed a gel-like substance and black particles floating in the solution. These reports prompted the FDA to take action.

The agency has classified the recall as precautionary, stating the risk of serious harm remains low. However, the incident raises concerns about quality control, especially for medicines designed for young patients. Neither Strides Pharma nor Taro Pharmaceuticals has publicly commented on the issue yet. The FDA's announcement did not mention similar recalls in other countries. Previous European recalls, such as those for ranitidine due to NDMA contamination, involved different medications and causes.

The recalled ibuprofen suspension was widely used for pain and fever relief in children. Parents and caregivers are advised to check their supplies and return affected bottles. The FDA continues to monitor the situation to ensure no further risks emerge.